Diabetes Drug Development: Seeing Light In The Dark Ages?
This article was originally published in Start Up
Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.
You may also be interested in...
Orexigen halts Contrave development for U.S., but the firm will appeal the division's "unprecedented" trial request through FDA's dispute resolution process.
Omthera Pharmaceuticals is betting that its so-called "free" fatty acid form of omega-3 will prove superior to other companies' ethyl esther versions at reducing blood triglyceride levels. An ethyl ester is a free fatty acid with an ethanol bond on it; that bond is broken in the intestines by pancreatic lipase, an enzyme specialized in breaking down fat. In Omthera's version of omega-3 fatty acid, that bond is broken already. The company thinks the difference will allow the free form to more effectively reduce TGL levels.
DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.